The present application is in the field of imaging reagents. In particular, the present application relates to labelled fluorocarbon imaging reagents, the preparation of the reagents, and their uses for imaging such as PET scanning.

The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to .sup.99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives stabilized .sup.99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.

A radioactive thermogel suspension, including a thermogel and a plurality of radioactive yttrium phosphate particles suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 um and 10 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

A radioactive yttrium phosphate suspension, including a phosphate buffered saline solution and a plurality of radioactive yttrium phosphate particles suspended in the phosphate buffered saline solution. The plurality of radioactive yttrium phosphate particles are between 0.1 um to 2 um in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 40 mg/ml to 125 mg/ml.

A visualizable radioactive carbon microsphere (CMS) suspension, a preparation method, and a use thereof are provided. Every 1 mL of the visualizable radioactive CMS suspension includes: CMS: 10 mg to 500 mg; a therapeutic radionuclide with an activity of 5 mCi to 500 mCi; an imaging radionuclide with an activity of 0.1 mCi to 100 mCi; a small organic molecule: 0 mg to 100 mg; and a first solution: 0.1 mL to 1.0 mL. The preparation method mainly includes a process of allowing the CMS to adsorb the small organic molecule, the therapeutic radionuclide, and the imaging zirconium [.sup.89Zr]. The visualizable radioactive CMS suspension can realize both local radiotherapy and real-time imaging of a solid tumor lesion, and thus achieves the visualized treatment of a tumor, which provides a new radioactive CMS product that integrates diagnosis and treatment.

A composition comprising including a homogeneous tin-117m colloid comprising tin-117m, and an ascorbic acid is provided, the composition naturally has a white coloration. The composition is visually distinct from a conventional homogeneous tin-117m colloid because conventional colloids have an orange-yellow color. The addition of ascorbic acid changes the color of the composition without adding toxicity and without changing the therapeutic effects of the homogeneous tin-117m colloid. A use and a method of making the same is also provided.

Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T.sub.1/T.sub.2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.

Described are methods for preparing radionuclides, such as radionuclides having a high specific activity. The disclosed methods include irradiating target nuclide materials, in solution, with a neutron source. The radionuclides can be separated from the target nuclide material by providing a solid carbon nanostructured material, as a suspension of solids, proximal to the target nuclide material in solution and using the recoil to drive adsorption of the radionuclide onto the solid carbon nanostructured material to transfer the radionuclides from the liquid phase (in solution) to the solid phase (adsorbed to the suspended solid carbon nanostructured material). One or more surfactants can be incorporated into the solution to facilitate formation of a stable suspension of the solid carbon nanostructured material.

A radioactive thermogel suspension, including a thermogel and a plurality of insoluble radioactive isotope phosphate particles, such as yttrium phosphate, suspended in the thermogel. The thermogel is PLGA-g-PEG. The thermogel contains less than 65 ppm stannous octanoate. The plurality of radioactive yttrium phosphate particles are between 0.03 .Math.m and 10 .Math.m in diameter. The plurality of radioactive yttrium phosphate particles are generally spherical. The YPO.sub.4 particle concentration is in the range of 3 mg/ml to 100 mg/ml.

The present invention relates to stable pharmaceutical compositions of sulfur colloid, which advantageously provide a high radiochemical purity to .sup.99mTc-pertechnetate without causing the gel formation. The compositions include pre-lyophilized and lyophilized compositions of sulfur colloid. It also relates to a non-radioactive kit which upon reconstitution with .sup.99mTc-pertechnetate solution gives stabilized .sup.99mmTc-Sulfur colloid radiopharmaceutical composition. Further, the process for preparation of said compositions and their use for diagnostic purposes are also disclosed.